and Sanofi/Regeneron's Praluent (alirocumab), which have list prices of $14,000 each. Express Scripts now expects to spend no more than $750 million on the drugs in 2016, far lower than industry ...

In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...

The FTC sued CVS Caremark, OptumRx and Express Scripts and their group purchasing organizations in September accusing the companies of "rigging" the insulin market and driving up prices.

Helping All Patients Benefit Directly from Express Scripts' Drug Price Negotiations While today more than 80% of Express Scripts' patients pay less than $100 per year for their prescriptions ...